Abstract: A system, method, device, and computer program product to extract and gather peak information from an automated sequencer of bioinformatics into a peak database, and to manipulate and analyze the peak information within the database.

Abstract: The invention concerns a method for obtaining an antiserum directed against a proteinic toxin by administering to an animal a solution comprising a genetic construct encoding a toxin immunogenic fragment, then applying an electric field in the administering zone, and isolating the serum. The invention also concerns the antiserum obtainable by the method as well as the use of the solution for making a medicine for preventing or treating a toxic effect related to absorption by a mammal of a toxin. The invention is characterized in that said medicine is formulated to be administered by electrotransfer.

Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.

Abstract: The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents.

Abstract: Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.

Abstract: The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerases (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.

Abstract: The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue.

Abstract: The present invention relates to polypeptides that inhibit the NF-&kgr;B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.

Abstract: A subject of the invention is the use of at least one cytosolic phospholipase A2 (cPLA2) inhibitor in the preparation of a medicament intended for the preventive and/or curative symptomatic treatment of cystic fibrosis, particularly of the increased secretion of mucus in cystic fibrosis.

Abstract: The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.

Abstract: The invention of the present application relates to a method for obtaining antibodies directed against a carbohydrate moiety contained in a carbohydrate peptide conjugate, by administering to a subject a composition containing a carbohydrate peptide conjugate and collecting the antibodies directed against the said carbohydrate moiety from a serum previously obtained from the subject.

Abstract: Polypeptides are provided, which are useful to produce specific monoclonal or polyclonal antibodies that serve as detection means in order to characterize any staphylococcal strain carrying genes encoding resistance to streptogramin A or to streptogramin B.

Abstract: A method of detecting a curvilinear object of a noisy image. The method includes filtering the noisy image in accordance with a two dimensional line profile. The line profile is selected within a class of steerable filters.

Abstract: The invention provides new insights into the manner in which cells evolve and age thereby providing methods for assessing and studying those processes.

Abstract: The present invention relates to methods for evaluating and predicting clinical outcomes in patients by measuring levels of sIP-10 protein expression as well as therapies using sIP-10 and its fragments.

Abstract: The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that binds to said modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving a chronic pain and/or neuron loss.

Abstract: The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal or monoclonal antibodies pre-selected for their high affinity for said NS1 protein hexameric in shape.

Abstract: The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human.

Abstract: The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample.

Abstract: The present invention relates to a method of detection of the presence of at least one domain of interest on a macromolecule to test, wherein said method comprises the following steps: a) determining beforehand at least two target regions on the domain of interest, designing and obtaining corresponding labeled probes of each target region, named set of probe of the domain of interest, the position of these probes one compared to the others being chosen and forming the specific signature of said domain of interest on the macromolecule to test; b) after spreading of the macromolecule to test on which the probes obtained in step a) are bound, detection of the position one compared to the others of the probes bound on the linearized macromolecule, the detection of the signature of a domain of interest indicating the presence of said domain of interest on the macromolecule to test, and conversely the absence of detection of signature or part of signature of a domain of interest indicating the absence of said domai